Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Sep 9, 2015 (11 years ago)

Bravelle 75 IU

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Subpotent Drug

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Bravelle 75 IU (urofollitropin for injection, purified) For Subcutaneous or Intramuscular Injection Only, 1 Carton (contains 5 single dose vials of Bravelle, 5 single dose vials of 0.9% Sodium Chloride Inj., USP, 2 mL, and 5 Q-Cap Vial Adaptors) , Rx Only, Manufactured for: Ferring Pharmaceuticals, Inc. Parsippany, NJ 07054, By: Ferring Gmbh, Kiel Germany, NDC 55566-8505-6

Affected NDC 55566-8505-06

Compare with the code on your package — it is the most precise check available.

Recalling firm
Ferring Pharmaceuticals Inc
NDC code
55566-8505-6
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0015-2016 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Ferring Pharmaceuticals Inc

All 2015 recalls
Class II · Moderate risk

Endometrin

cGMP deviations: potential for Microbial Contamination of Non-Sterile Products

Terminated Microbial contamination Ferring Pharmaceuticals Inc NDC 55566-6500-03 D-0879-2023
Class II · Moderate risk

ZOMA-Jet 10 Demonstration Kit

Defective Delivery System: customer complaints concerning the injector pen breaking apart and disintegrating into pieces.

Terminated Packaging defect Ferring Pharmaceuticals Inc D-0318-2021
Class II · Moderate risk

ZOMA-Jet 5 Demonstration Kit

Defective Delivery System: customer complaints concerning the injector pen breaking apart and disintegrating into pieces.

Terminated Packaging defect Ferring Pharmaceuticals Inc D-0317-2021
Class III · Low risk

Menopur 75 IU

Failed pH specifications: Out of Specification pH results for 0.9% Sodium Chloride, USP

Terminated Failed specification Ferring Pharmaceuticals Inc NDC 55566-7501-2 D-0299-2021

Other wrong potency / content recalls from 2015

All wrong potency / content recalls
Class III · Low risk

NORepinephrine Bitartrate

Subpotent Drug; confirmed results by FDA analysis after customer complaints of discoloration

Terminated Wrong potency / content Pharmedium Services, LLC NDC 61553-127-61 D-0778-2016
Class III · Low risk

NORepinephrine Bitartrate

Subpotent Drug; confirmed results by FDA analysis after customer complaints of discoloration

Terminated Wrong potency / content Pharmedium Services, LLC NDC 61553-134-61 D-0777-2016
Class III · Low risk

Lindane Lotion

Super-Potent Drug: Out of Specification Assay test results were reported for stability samples.

Terminated Wrong potency / content Morton Grove Pharmaceuticals, Inc. NDC 60432-833-60 D-0571-2016
Class I · High risk

Vitamin Supplement

Superpotent Drug: The vitamin supplement contains an extremely high level of vitamin D3 (Cholecalciferol).

Ongoing Wrong potency / content Glades Drugs Inc. D-0669-2016